HOW TO CUSTOMIZE TREATMENT

kybella®
(deoxycholic acid) injection 10 mg/mL

Kount the Treatments

The KYBELLA® Kount (2+/4+) helps you and your patient discuss the estimated number of treatment sessions for their desired reduction of submental fullness.

Tailor the number of treatments to the submental fat distribution and your patient's aesthetic goals.

2+ TREATMENTS

- 2 or 3 treatments to achieve desired aesthetic goals
- Two or more (2+) treatment sessions may be appropriate for some patients with moderate to severe submental fullness based on clinician assessment and patient aesthetic goals

ADRA, AGE 35
3 treatments: 12 mL total, 6 vials total

4+ TREATMENTS

- 4, 5, or 6 treatments to achieve desired aesthetic goals
- Four or more (4+) treatment sessions may be appropriate for some patients with moderate to severe submental fullness based on clinician assessment and patient aesthetic goals

JASON, AGE 36
6 treatments: 28 mL total, 14 vials total

Real patients. Results may vary. Unretouched photos taken before and after treatment.
Results are represented over the course of treatment; not all treatments are shown. Number of treatments is tailored* to the amount of submental fat and aesthetic goals; 59% of subjects received 6 KYBELLA® treatments in clinical trials.[1]

*Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart.[1]

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Please see additional Important Safety Information on back page.

HOW TO CUSTOMIZE TREATMENT

kybella®
(deoxycholic acid) injection 10 mg/mL

Kalculate the Dose

One way to determine the patient's total dose is knowing how the number of dots in the treatment area translates to the number of vials of KYBELLA®.

The safe and effective use of KYBELLA® depends on the use of the correct number of and locations for injections, proper needle placement, and proper administration techniques.

10 DOTS : 1 VIAL

- For every 10 dots, you will need 1 vial[1]
  - Dose 0.2 mL per injection site and space 1 cm apart
- Round up to ensure adequate dosage amount
- Do not exceed 5 vials (or 10 mL) in a single treatment session[1]



Number of dots : Number of vials[1]
10 : 1
20 : 2
30 : 3
40 : 4
50 : 5

Color of dots on image above are for visual purposes only. Shaded shapes are to help visualize the number of dots on the spacing grid. Dotted lines indicate perforations available to customize grid size to patient's individual anatomy.

Review full treatment protocols in the KYBELLA® **A.C.T.** Now Guide, and visit the website for more information.

Healthcare professionals administering KYBELLA® must understand the relevant submental anatomy and associated neuromuscular structures in the area involved, as well as any alterations to the anatomy due to prior surgical or aesthetic procedures.

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration, Necrosis, and Infection
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration, necrosis, and infection have been reported with administration of KYBELLA®. Some cases of injection site infection have included cellulitis and abscess requiring antibiotic treatment and incision and drainage. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see accompanying full Prescribing Information, or visit https://www.rxabbvie.com/pdf/kybella_pi.pdf

REFERENCE: 1. KYBELLA® Prescribing Information, October 2022.

Allergan Aesthetics
an AbbVie company

KYB153160-v2 12/22 020047